The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn about the medication’s risk for weight loss and other adverse reactions in patients younger than 6 years of age.
This article was originally published on MedicalXpress.com
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
© 2025 SimplyWell.ca